Sultopride

Sultopride
Clinical data

Trade names	Barnetil, Barnotil, Topral
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, IM
ATC code	N05AL02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Biological half-life	3–5 hours
Identifiers
IUPAC name N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
CAS Number	53583-79-2^N
PubChem CID	5357
ChemSpider	5164^Y
UNII	AA0G3TW31W
KEGG	D08549^Y
ChEMBL	CHEMBL277945^Y
ECHA InfoCard	100.053.293
Chemical and physical data
Formula	C₁₇H₂₆N₂O₄S
Molar mass	354.46 g/mol
3D model (Jmol)	Interactive image
SMILES O=S(=O)(c1cc(c(OC)cc1)C(=O)NCC2N(CC)CCC2)CC
InChI InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)^Y Key:UNRHXEPDKXPRTM-UHFFFAOYSA-N^Y
^NY (what is this?)

Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D₂ and D₃ receptor antagonist. It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.